GutBiomeTech
Microbiome-based live biotherapeutic products and NGS analysis.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | KRW200m | Seed | |
| Total Funding | 000k | ||
GutBiomeTech is a pharmabiotics company specializing in the research of the gut microbiome to develop live biotherapeutic products. The company was established on October 7, 2022, by CEO Wan-Kyu Lee. Lee, who also serves as a professor at Chungbuk National University's College of Veterinary Medicine, brings over four decades of experience in culturing and analyzing anaerobic microbiomes.
The company's core business revolves around several key areas. It develops probiotics for treating inflammatory bowel diseases (IBD), as well as for applications in anti-obesity, immune enhancement, and the prevention of heavy metal accumulation. Additionally, GutBiomeTech creates health functional foods for companion animals. A significant part of its operations includes providing Next-Generation Sequencing (NGS) analysis services, such as 16S/ITS Metagenomic Sequencing and Whole Genome Sequencing, to analyze gut microbiomes. The firm possesses a genetic analysis platform and has established a human microbiome banking system, securing a wide range of strains from both healthy individuals and IBD patients.
GutBiomeTech's business model appears to be driven by R&D, sales of analysis services, and future commercialization of its therapeutic products. The company achieved its first revenue in February 2023 from its NGS analysis services and kit sales. It has secured multiple rounds of investment from venture capital firms like Oracle Venture Investment and CNV Partners, and has been selected for several government-backed R&D and startup support programs, including the deep tech TIPS program by the Ministry of SMEs and Startups. The company holds ISO certifications for quality and environmental management and has obtained a manufacturing license for in-vitro diagnostic medical devices.
Keywords: microbiome therapeutics, live biotherapeutics, pharmabiotics, next-generation sequencing, NGS analysis, gut health, probiotics, inflammatory bowel disease, IBD treatment, metagenomics, anaerobic microbiomes, companion animal health, biometrics, genetic analysis, fecal microbiome, Wan-Kyu Lee, microbial biotechnology